Movement Alert｜PHARMARON Rises 3.15% in Regular Trading, CRO Sector Momentum Extends on AI Pharma Catalyst and Policy Tailwinds

Market Focus09-22

On September 22, PHARMARON rose 3.15% in regular trading, trading at HKD 31.38 per share, with turnover of approximately HKD 112 million. The gain extends consecutive sessions of strength in the CRO sector.

On the news front, the broader CRO sector continues to rally on multiple catalysts. Novo Nordisk and Anthropic recently announced an AI-driven drug discovery collaboration, while cumulative domestic innovative drug licensing-out deal value has surpassed USD 120 billion, signaling robust R&D budgets at pharmaceutical companies. CRO firms are seeing order backlogs improve in both volume and pricing. Additionally, a joint directive from ten government departments supporting innovative drug development continues to fuel policy tailwinds.

On the institutional side, Goldman Sachs has explicitly endorsed a recovery thesis for China's CRO/CDMO industry and assigned PHARMARON a Buy rating. Daiwa, Bank of America, and Morgan Stanley have raised their target prices to HKD 38.5, HKD 38.4, and HKD 35.6, respectively. Within the Life Sciences Tools & Services sector, peers including WUXI APPTEC rose 1.54%, WUXI BIO gained 1.23%, and XTALPI advanced 4.77%.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1103378128?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-09-22 10:33","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1103378128","market":"us","top_or_hot":-1,"title":"Movement Alert｜PHARMARON Rises 3.15% in Regular Trading, CRO Sector Momentum Extends on AI Pharma Catalyst and Policy Tailwinds","media":"Market Focus","content":"<p><p>On September 22, PHARMARON rose 3.15% in regular trading, trading at HKD 31.38 per share, with turnover of approximately HKD 112 million. The gain extends consecutive sessions of strength in the CRO sector.</p><p>On the news front, the broader CRO sector continues to rally on multiple catalysts. Novo Nordisk and Anthropic recently announced an AI-driven drug discovery collaboration, while cumulative domestic innovative drug licensing-out deal value has surpassed USD 120 billion, signaling robust R&D budgets at pharmaceutical companies. CRO firms are seeing order backlogs improve in both volume and pricing. Additionally, a joint directive from ten government departments supporting innovative drug development continues to fuel policy tailwinds.</p><p>On the institutional side, Goldman Sachs has explicitly endorsed a recovery thesis for China's CRO/CDMO industry and assigned PHARMARON a Buy rating. Daiwa, Bank of America, and Morgan Stanley have raised their target prices to HKD 38.5, HKD 38.4, and HKD 35.6, respectively. Within the Life Sciences Tools & Services sector, peers including WUXI APPTEC rose 1.54%, WUXI BIO gained 1.23%, and XTALPI advanced 4.77%.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜PHARMARON Rises 3.15% in Regular Trading, CRO Sector Momentum Extends on AI Pharma Catalyst and Policy Tailwinds</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜PHARMARON Rises 3.15% in Regular Trading, CRO Sector Momentum Extends on AI Pharma Catalyst and Policy Tailwinds\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-09-22 10:33</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On September 22, PHARMARON rose 3.15% in regular trading, trading at HKD 31.38 per share, with turnover of approximately HKD 112 million. The gain extends consecutive sessions of strength in the CRO sector.</p><p>On the news front, the broader CRO sector continues to rally on multiple catalysts. Novo Nordisk and Anthropic recently announced an AI-driven drug discovery collaboration, while cumulative domestic innovative drug licensing-out deal value has surpassed USD 120 billion, signaling robust R&D budgets at pharmaceutical companies. CRO firms are seeing order backlogs improve in both volume and pricing. Additionally, a joint directive from ten government departments supporting innovative drug development continues to fuel policy tailwinds.</p><p>On the institutional side, Goldman Sachs has explicitly endorsed a recovery thesis for China's CRO/CDMO industry and assigned PHARMARON a Buy rating. Daiwa, Bank of America, and Morgan Stanley have raised their target prices to HKD 38.5, HKD 38.4, and HKD 35.6, respectively. Within the Life Sciences Tools & Services sector, peers including WUXI APPTEC rose 1.54%, WUXI BIO gained 1.23%, and XTALPI advanced 4.77%.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"03759","symbol_name":"康龙化成","start_time":0,"source_url":"","article_id":"1103378128","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1103378128","pubTimestamp":1790044433,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On September 22, PHARMARON rose 3.15% in regular trading, trading at HKD 31.38 per share, with turnover of approximately HKD 112 million. The gain extends consecutive sessions of strength in the CRO...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"03759":"康龙化成"},"translate_title":"走势提醒|康龙化成常规交易上涨3.15%，人工智能制药催化剂和政策推动下CRO板块势头延续","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"03759":1},"content_text":"On September 22, PHARMARON rose 3.15% in regular trading, trading at HKD 31.38 per share, with turnover of approximately HKD 112 million. The gain extends consecutive sessions of strength in the CRO sector.On the news front, the broader CRO sector continues to rally on multiple catalysts. Novo Nordisk and Anthropic recently announced an AI-driven drug discovery collaboration, while cumulative domestic innovative drug licensing-out deal value has surpassed USD 120 billion, signaling robust R&D budgets at pharmaceutical companies. CRO firms are seeing order backlogs improve in both volume and pricing. Additionally, a joint directive from ten government departments supporting innovative drug development continues to fuel policy tailwinds.On the institutional side, Goldman Sachs has explicitly endorsed a recovery thesis for China's CRO/CDMO industry and assigned PHARMARON a Buy rating. Daiwa, Bank of America, and Morgan Stanley have raised their target prices to HKD 38.5, HKD 38.4, and HKD 35.6, respectively. Within the Life Sciences Tools & Services sector, peers including WUXI APPTEC rose 1.54%, WUXI BIO gained 1.23%, and XTALPI advanced 4.77%.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1103378128","isCrawlerRequest":true}